Pharma · Generics
Detailing and sample spend produced no prescribing lift.
This marketing & margin audit identified $64k in wasted annual spend in a Pharma business — evidenced, senior-reviewed, and delivered in 7 days.
The business
A generics manufacturer ran a large field force detailing HCPs and distributing samples, a traditional and expensive part of its commercial model. Coverage was broad and activity metrics looked healthy, so which HCPs the detailing and samples actually moved — and which received the same investment with no change in prescribing — was never rigorously analyzed.
What triggered the audit
Detailing and sample spend was substantial, yet prescribing growth didn’t obviously track it, hinting much of the effort landed on HCPs it never moved. The audit matched detailing and sample investment per HCP against actual prescribing change, testing where the spend genuinely drove lift.
What the audit found
A large share of the detailing and sample budget was producing no prescribing lift at all. Matching investment to outcomes HCP by HCP showed that the field force was allocated by broad coverage targets rather than by responsiveness, so a significant segment of physicians received regular visits and samples while their prescribing didn’t move at all — either because they were already loyal, structurally unreachable, or simply unresponsive to detailing. Because the model measured reach and activity rather than prescribing change, this dead-weight effort was invisible, and the same expensive investment kept flowing to non-responders year after year. Reallocated away from them, the no-lift detailing and samples represented roughly $64k a year of wasted commercial spend.
What we changed
Matched detailing and sample investment to actual prescribing change per HCP, exposing exactly which physicians the expensive effort never moved.
Reallocated field-force time and samples away from non-responders and toward the HCPs where detailing genuinely drives prescribing lift.
Set coverage targets by responsiveness rather than broad reach, so the most expensive commercial effort follows measurable impact.
Made prescribing lift per detailing dollar a monitored metric, so no-lift spend can’t quietly persist across the field force season after season the way it had for years.
The result
$64k a year recovered by directing detailing and samples to the HCPs it actually moves — an 11× return on the $5,950 Audit + Sprint fee. For any pharma commercial team, activity metrics are the trap: reach and call counts look healthy while a large slice of expensive effort lands on physicians it never influences. If you measure coverage rather than prescribing lift, you’re likely detailing non-responders year after year. It takes matching investment to prescribing change to see it — a fixed-fee audit does that in days.
From kickoff to signed-off findings: 7 days — inside our fixed 5–7 day window.